NCI Funding Opportunity Announcement
Friday, December 18, 2015
Notice of Intent to Publish a Funding Opportunity Announcement for Cooperative Agreements to Develop Targeted Agents for Use with Systemic Agents Plus Radiotherapy (U01)
Notice Number: NOT-CA-16-005
Release Date: December 16, 2015
Estimated Publication Date of Announcement: Spring 2016
First Estimated Application Due Date: June/July 2016
Earliest Estimated Award Date: January 2017
Earliest Estimated Start Date: April 2017
Issued By: National Cancer Institute (NCI)
The National Cancer Institute intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for research on in vivo and in vitro testing of Cancer Therapy Evaluation Program (CTEP) investigational, molecularly targeted anti-tumor drugs as integral components of chemo-radiotherapy. The Consortium to be established through this initiative will be expected to develop a rigorous preclinical testing program for these agents when combined with radiation and systemic chemotherapy. Developing pilot studies aimed at defining mechanisms of activity for combinatorial treatments will be encouraged. The goal of the individual projects will be to generate reliable data that can be validated within the Consortium. The overarching purpose of the initiative is to inform new agent prioritization decisions, and clinical trial design in order to increase the likelihood of positive clinical trials. The goal is to develop more effective treatments for cancers treated with chemo-radiation.
This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and well-designed projects that address the goals of this FOA
The FOA is expected to be published in the Spring of 2016 with an expected application due date in early Summer 2016.
This FOA will utilize the U01 activity code. Details of the planned FOA are provided below.
CLICK HERE TO READ FULL ARTICLE
Please Direct All Inquiries To Dr. Eric Bernhard, Chief of Radiotherapy Development Branch (240-276-5704, email@example.com )